Wegovy (Semaglutide) Injection

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:

• Adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
• Paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity)

Your brain gets signals from different places in your body. Some of these signals are called appetite hormones that help regulate how much food you eat. Wegovy works similarly to one of these natural appetite hormones, so you eat fewer calories, and lose weight.

The primary efficacy parameters were mean percent change in body weight and the percentages of patients achieving greater than or equal to 5% weight loss from baseline to week 68. After 68 weeks, treatment with Wegovy resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with Wegovy achieved 5%, 10% and 15% weight loss than those treated with placebo

Administer Wegovy once weekly, on the same day each week, at any time of day, with or without meals.

Administer Wegovy subcutaneously in the abdomen, thigh,or upper arm. The time of day and the injection site can be changed without dose adjustment.

• If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer Wegovy as soon as possible. If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on the regularly scheduled day of the week.
• If 2 or more consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate Wegovy and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment.

Most common adverse reactions (incidence ≥ 5%) in adults or paediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease, and nasopharyngitis

Some medicines are not suitable for people with certain conditions or on particular medicines. For this reason, it is very important you declare your full medical history to our Click Doctors via our online consultations so that a proper judgement can be made on its use.

Do not use Wegovy:

• If you are allergic to its active ingredients or any of its other ingredients
• Have a BMI of less than 27
• If you have chronic malabsorption syndrome
• If you have cholestasis
• If you are breast-feeding

The use of an additional contraceptive method is recommended to prevent possible failure of oral contraception that could occur in case of severe diarrhoea.

For full information on how to take, side effects and precautions, it is important that you carefully read the patient information leaflet.

It is possible to travel with your Wegovy pen: 

• When travelling by air, keep your Wegovy pen with you or in your carry-on, as it may freeze in the baggage compartment. Be sure to check with the airline to see if they have any specific baggage rules. 
• If needed, Wegovy may be stored between 15°c and 30°c in the original carton for up to 56 days.